# Will a bill curbing pharmaceutical monopolies become law?

Before Jan 4, 2027

Updated: May 12, 2026

Category: Politics

Tags: Congress

HTML: /markets/politics/congress/will-a-bill-curbing-pharmaceutical-monopolies-become-law/

## Short Answer

**Key takeaway.** Both the **model** and the **market** expect a bill curbing pharmaceutical monopolies to become law before Jan 4, 2027, with no compelling evidence of mispricing.

## Key Claims (January 2026)

**- - 2026 midterm elections may shift legislative control impacting regulations.** - Congressional leaders appear to advocate for curbing pharmaceutical monopolies.
- Procedural hurdles and late 2026 deadlines limit bill progress.
- H.R. 3546 was introduced in the 119th Congress.
- A **market** tracks the potential enactment of a new monopolies act.

### Why This Matters (GEO)

- AI agents extract claims, not arguments.
- Improves citation probability in summaries and answer cards.
- Enables fact stitching across multiple sources.

## Executive Verdict

**Key takeaway.** **Model** and **market** both estimate **17%** **probability** (5.9x payout), due to legislative and 2026 timeline hurdles.

### Who Wins and Why

| Outcome | Market | Model | Why |
| --- | --- | --- | --- |
| Before Jan 4, 2027 | 17.0% | 17.0% | Legislation targeting pharmaceutical monopolies typically encounters strong industry opposition in Congress. |

## Model vs Market

- Model Probability: 17.0% (Yes)
- Market Probability: 17.0% (Yes)
- Yes refers to: Before Jan 4, 2027
- Edge: +0.0pp
- Expected Return: +0.0%
- R-Score: 0.00
- Total Volume: $1,958.96
- 24h Volume: $0
- Open Interest: $1,038.62

- Expiration: January 4, 2027

## Market Behavior & Price Dynamics

This market has exhibited a sideways trend with minimal volatility, trading within a very narrow two-point range between 15.0% and 17.0%. These price points have served as the effective support and resistance levels for the market. The price began at 15.0% and experienced a minor increase to 17.0%, where it has remained. There have been no significant price spikes or drops to analyze, as the market has remained stable and confined within this tight band.

The total trading volume is extremely low, at only 29 contracts, which indicates a lack of market participation and low conviction from traders. This low engagement suggests that there has been no significant news or catalyst to drive interest or shift sentiment. The market's persistent low probability, currently at 17.0%, likely reflects the impact of existing legislation. Given that the Inflation Reduction Act of 2022 granted Medicare drug price negotiation authority and the Consolidated Appropriations Act, 2026 was signed into law with substantial reforms for Pharmacy Benefit Managers, the market sentiment appears to be that the impetus for passing another major bill on this topic before the 2027 deadline is low.

## Contract Snapshot

The market resolves to "Yes" if a bill titled "Patients Before Monopolies Act," or an equivalent bill curbing monopolistic practices (specifically joint ownership of PBM and Pharmacy businesses) in healthcare or pharmaceuticals, becomes law. If no such bill becomes law by January 4, 2027, the market resolves to "No." The outcome will be verified from the Library of Congress, and the market closes early if the event occurs, with a projected payout 30 minutes after closing.

## Market Discussion

A bill aimed at curbing pharmaceutical monopolies is demonstrating significant bipartisan momentum in the U.S. Congress, with several measures advancing in the Senate Judiciary Committee [[^]](https://harshbarger.house.gov/media/press-releases/rep-harshbarger-introduces-legislation-eliminate-pbm-monopoly-pharmaceutical). These legislative efforts seek to address conflicts of interest, prevent "product hopping," and enhance transparency to foster competition, which could lead to lower drug costs and billions in taxpayer savings [[^]](https://harshbarger.house.gov/media/press-releases/rep-harshbarger-introduces-legislation-eliminate-pbm-monopoly-pharmaceutical). Despite historical challenges, there is a current sense of urgency for reforms within the 119th Congress, driven by widespread public discontent over high drug prices [[^]](https://www.forbes.com/sites/joshuacohen/2025/04/06/drug-patent-reforms-been-postponed-repeatedly-is-the-119th-congress-ready-to-act/).

## Market Data

| Contract | Yes Bid | Yes Ask | Last Price | Volume | Open Interest |
| --- | --- | --- | --- | --- | --- |
| Before Jan 4, 2027 | 9% | 15% | 17% | $1,958.96 | $1,038.62 |

## How might the outcome of the 2026 midterm elections shift the legislative agenda for or against new pharmaceutical monopoly regulations before the 119th Congress adjourns?

2026 House Forecast | Leaning Democratic (April 2026) [[^]](https://uspollingdata.com/news/2026-election-forecast/)[[^]](https://www.270towin.com/2026-senate-election-predictions/)[[^]](https://www.270towin.com/2026-house-election-predictions/) |
2026 Senate Forecast | Roughly a toss-up (April 2026) [[^]](https://uspollingdata.com/news/2026-election-forecast/)[[^]](https://www.270towin.com/2026-senate-election-predictions/)[[^]](https://www.270towin.com/2026-house-election-predictions/) |
Drug Policy Focus | Drug pricing and competition expected to remain a focus for both parties [[^]](https://uspollingdata.com/news/2026-election-forecast/)[[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm)[[^]](https://www.pwc.com/us/en/industries/health-industries/health-policy-and-intelligence-institute/us-healthcare-policy-2026-midterms.html)[[^]](https://www.ajmc.com/view/health-policy-volatility-regulatory-shifts-shape-outlook-ahead-of-2026-midterms)[[^]](https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1743160/2026-life-sciences-policy-outlook) |

**The 2026 midterm elections may significantly alter legislative control, potentially impacting new pharmaceutical monopoly regulations such as H.R**

The 2026 midterm elections may significantly alter legislative control, potentially impacting new pharmaceutical monopoly regulations such as H.R. 3546 [[^]](https://uspollingdata.com/news/2026-election-forecast/)[[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm)[[^]](https://www.pwc.com/us/en/industries/health-industries/health-policy-and-intelligence-institute/us-healthcare-policy-2026-midterms.html)[[^]](https://www.ajmc.com/view/health-policy-volatility-regulatory-shifts-shape-outlook-ahead-of-2026-midterms)[[^]](https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1743160/2026-life-sciences-policy-outlook). As of April 2026, forecasts indicate the House of Representatives is leaning Democratic, while the Senate remains a toss-up [[^]](https://uspollingdata.com/news/2026-election-forecast/)[[^]](https://www.270towin.com/2026-senate-election-predictions/)[[^]](https://www.270towin.com/2026-house-election-predictions/). These shifts could lead to changes in committee leadership and influence the scheduling of high-profile drug policy bills [[^]](https://uspollingdata.com/news/2026-election-forecast/).

Drug pricing and competition will remain a key legislative priority, regardless of which party controls Congress [[^]](https://uspollingdata.com/news/2026-election-forecast/)[[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm)[[^]](https://www.pwc.com/us/en/industries/health-industries/health-policy-and-intelligence-institute/us-healthcare-policy-2026-midterms.html)[[^]](https://www.ajmc.com/view/health-policy-volatility-regulatory-shifts-shape-outlook-ahead-of-2026-midterms)[[^]](https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1743160/2026-life-sciences-policy-outlook). The increasing emphasis on affordability and transparency in healthcare ensures that issues like drug pricing, exclusivity, and competition will stay on the legislative agenda, though the specific methods for addressing them may differ based on the majority party [[^]](https://www.pwc.com/us/en/industries/health-industries/health-policy-and-intelligence-institute/us-healthcare-policy-2026-midterms.html)[[^]](https://www.ajmc.com/view/health-policy-volatility-regulatory-shifts-shape-outlook-ahead-of-2026-midterms)[[^]](https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1743160/2026-life-sciences-policy-outlook). For example, H.R. 3546 aims to reduce prescription drug prices by eliminating government-granted monopolies for manufacturers charging above-median prices, and it includes provisions for waiving exclusivities and issuing open licenses for "excessively priced" drugs [[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm).

Bipartisan consensus exists for certain pharmaceutical competition reforms within Congress [[^]](https://natlawreview.com/article/senate-judiciary-committee-pushes-pharma-patents-and-pricing-bills-forward)[[^]](https://www.govinfo.gov/link/bills/119/s/3716?link-type=pdf)[[^]](https://www.durbin.senate.gov/newsroom/press-releases/durbin-tillis-introduce-legislation-to-improve-coordination-between-uspto-and-fda-on-pharma-patents). This sustained support suggests that even if comprehensive "monopoly curbing" legislation faces obstacles, more focused measures aimed at fostering competition in patents and exclusivity are likely to advance before the 119th Congress adjourns [[^]](https://kalshi.com/markets/kxpatientsmonopolies/patients-before-monopolies-act-becomes-law)[[^]](https://natlawreview.com/article/senate-judiciary-committee-pushes-pharma-patents-and-pricing-bills-forward)[[^]](https://www.govinfo.gov/link/bills/119/s/3716?link-type=pdf)[[^]](https://www.durbin.senate.gov/newsroom/press-releases/durbin-tillis-introduce-legislation-to-improve-coordination-between-uspto-and-fda-on-pharma-patents).

## Beyond its bipartisan sponsors, what evidence of support or opposition for new monopoly curbs has emerged from leadership in the 119th Congress?

PBM Reform Advocate | Senate Majority Leader John Thune (R-SD) [[^]](https://www.republicanleader.senate.gov/newsroom/remarks/thune-republicans-policies-drive-down-health-care-costs)[[^]](https://www.sdpha.org/action-center) |
Drug Price Reduction Champion | Senator Bill Cassidy (R-LA) [[^]](https://www.help.senate.gov/rep/newsroom/press/president-trump-signs-cassidy-led-policy-lowering-drug-prices-protecting-families-from-corporate-middlemen-into-law) |
Opponent of Drug Cost Legislation | Speaker of the House Mike Johnson (R-LA) [[^]](https://www.protectourcare.org/another-extreme-maga-choice-to-lead-the-house-mike-johnsons-health-care-record-makes-him-an-abysmal-choice-for-speaker/) |

**Several congressional leaders advocate for curbing pharmaceutical monopolies**

Several congressional leaders advocate for curbing pharmaceutical monopolies. Senate Majority Leader John Thune (R-SD) champions Pharmacy Benefit Manager (PBM) reform, promoting increased transparency and decoupling PBM compensation from drug list prices to reduce consumer costs [[^]](https://www.republicanleader.senate.gov/newsroom/remarks/thune-republicans-policies-drive-down-health-care-costs)[[^]](https://www.sdpha.org/action-center). Senator Bill Cassidy (R-LA), Chair of the Senate HELP Committee, has spearheaded policies to lower prescription drug prices and control healthcare middlemen, aiming for a balance between innovation and affordability [[^]](https://www.help.senate.gov/rep/newsroom/press/president-trump-signs-cassidy-led-policy-lowering-drug-prices-protecting-families-from-corporate-middlemen-into-law)[[^]](https://www.cassidy.senate.gov/about/issues/lowering-the-cost-of-health-care/)[[^]](https://www.help.senate.gov/rep/newsroom/press/video-ranking-member-cassidy-delivers-remarks-during-committee-hearing-on-weight-loss-drugs). Furthermore, Senator Chuck Grassley (R-IA) has contributed to drug pricing legislation, including the Drug Competition Enhancement Act [[^]](https://www.grassley.senate.gov/news/news-releases/grassley-cornyn-blumenthal-durbin-introduce-bill-to-spur-drug-pricing-competition), and Representative Pramila Jayapal (D-WA) co-chairs the "Monopoly Busters Caucus," which focuses on tackling corporate consolidation across various sectors, including healthcare [[^]](https://jayapal.house.gov/2025/04/09/jayapal-deluzio-ryan-craig-launch-monopoly-busters-caucus/)[[^]](https://deluzio.house.gov/media/press-releases/deluzio-jayapal-ryan-craig-launch-monopoly-busters-caucus)[[^]](https://craig.house.gov/media/press-releases/reps-craig-jayapal-deluzio-ryan-launch-monopoly-busters-caucus-fight-corporate)[[^]](https://www.knkx.org/politics/2026-02-03/democrats-monopoly-busters-caucus-seattle-hearing-food-affordability).

Other leaders voice opposition to aggressive monopoly curbs. Speaker of the House Mike Johnson (R-LA) has opposed legislation designed to lower drug costs, specifically efforts for Medicare drug price negotiation and provisions of the Inflation Reduction Act [[^]](https://www.protectourcare.org/another-extreme-maga-choice-to-lead-the-house-mike-johnsons-health-care-record-makes-him-an-abysmal-choice-for-speaker/). He also expressed concerns regarding a White House-proposed crackdown on the pharmaceutical industry [[^]](https://www.politico.com/live-updates/2025/05/01/congress/johnson-not-a-big-fan-of-drug-policy-white-house-wants-for-trumps-megabill-00320974). Representative Scott Fitzgerald (R-WI), who chairs the House Subcommittee on Administrative State, Regulatory Reform, and Antitrust, prioritizes reversing the "Biden Administration's anti-business agenda" and advocates for free-**market** competition. He cautions against "European style micromanagement" in antitrust policy, suggesting it could negatively impact industry profits and research and development [[^]](https://fitzgerald.house.gov/media/press-releases/fitzgerald-statement-being-named-antitrust-subcommittee-chairman)[[^]](https://www.vitallaw.com/news/antitrust-news-fitzgerald-named-new-leader-of-house-antitrust-subcommittee/ald016f7f007381ea40a8af20327c511fd454)[[^]](https://www.youtube.com/watch?v=CggOYf5c1bI)[[^]](https://about.bgov.com/insights/news/campaign-cash-follows-gop-senator-may-drug-price-firewall/)[[^]](https://news.bloomberglaw.com/health-law-and-business/sen-barrasso-big-pharma-capsule-drug-policies-overseas)[[^]](https://punchbowl.news/future-of/medicine/legislative-landscape/).

## What procedural hurdles and timeline constraints within the 119th Congress could prevent a new, complex healthcare bill from reaching a floor vote before January 2027?

Senate Target Adjournment | December 18, 2026 [[^]](https://www.senate.gov/legislative/resources/pdf/2026_calendar.pdf) |
House Target Last Session Day | December 17, 2026 [[^]](http://pressgallery.house.gov/schedules/2026-house-calendar) |
Floor Vote Target | Before January 2027 [[^]](https://www.senate.gov/legislative/resources/pdf/2026_calendar.pdf) |

**Key legislative deadlines in late 2026 severely limit floor vote opportunities**

Key legislative deadlines in late 2026 severely limit floor vote opportunities. A new, complex healthcare bill faces significant procedural hurdles and timeline constraints within the 119th Congress, making it challenging to reach a floor vote before January 2027. The Senate's target adjournment for its second session is December 18, 2026 [[^]](https://www.senate.gov/legislative/resources/pdf/2026_calendar.pdf). Similarly, the House’s 2026 calendar sets its target last day of session for December 17, 2026 [[^]](http://pressgallery.house.gov/schedules/2026-house-calendar). Any new, complex healthcare or pharmaceutical bill not ready for floor consideration by mid-to-late December is especially likely to miss a pre–January 2027 floor vote due to these tight windows [[^]](https://www.senate.gov/legislative/resources/pdf/2026_calendar.pdf).

Extensive procedural requirements pose significant obstacles for complex healthcare legislation. The 119th Congress mandates committee consideration and reporting before a bill can be scheduled for floor action, meaning a new, complex healthcare bill introduced too late in the session may not clear committees in time [[^]](https://www.congress.gov/legislative-process/committee-consideration). These complex policy packages commonly require multiple procedural steps across both chambers, including committee referral, hearings, markup, reporting, and then floor scheduling and debate with amendment management [[^]](https://www.congress.gov/legislative-process/committee-consideration). This extensive process increases the risk that such bills cannot be arranged into a floor timetable that resolves before early January 2027 [[^]](https://www.congress.gov/legislative-process/committee-consideration). For instance, legislation like H.R. 3546, which proposes ending government-granted monopolies for excessively priced drugs, exemplifies the typical complexity of "curbing monopolies" healthcare legislation [[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm). Similarly, the bipartisan Durbin-Cassidy REMEDY Act, aimed at removing incentives for brand-name manufacturers to extend monopolies, indicates that such efforts require careful Senate procedural handling before becoming law [[^]](https://www.durbin.senate.gov/newsroom/press-releases/durbin-cassidy-remedy-act-to-lower-prescription-costs-by-promoting-generic-competition).

## What Could Change the Odds

**A market on Kalshi, titled "Will a bill curbing pharmaceutical monopolies become law.** Odds & Predictions 2027," is tracking the potential enactment of a "Patients Before Monopolies Act" [[^]](https://kalshi.com/markets/kxpatientsmonopolies/patients-before-monopolies-act-becomes-law). This **market** is framed around a 2027 outcome, not reflecting confirmed enactment [[^]](https://kalshi.com/markets/kxpatientsmonopolies/patients-before-monopolies-act-becomes-law).

**Another potential catalyst is the introduction of H.R.** 3546 (119th Congress) on May 21, 2025 [[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm). This bill proposes to end "government-granted monopolies" for drug manufacturers charging excessively priced drugs [[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm). The proposal includes waiving or voiding government-granted exclusivities and granting open, non-exclusive licenses once the Secretary determines a brand-name drug is "excessively priced" [[^]](https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htm).

## Key Dates & Catalysts

- **Expiration:** January 04, 2027
- **Closes:** January 04, 2027

## Decision-Flipping Events

- A **market** on Kalshi, titled "Will a bill curbing pharmaceutical monopolies become law?
- Odds & Predictions 2027," is tracking the potential enactment of a "Patients Before Monopolies Act" [^] .
- This **market** is framed around a 2027 outcome, not reflecting confirmed enactment [^] .
- Another potential catalyst is the introduction of H.R.

## Related Research Reports

- [EU has a new member before 2030?](/markets/politics/international/eu-has-a-new-member-before-2030/)
- [Will Trump's birthright citizenship order come into effect?](/markets/politics/scotus-courts/will-trump-s-birthright-citizenship-order-come-into-effect/)
- [Will Trump create a $250 bill featuring himself?](/markets/politics/congress/will-trump-create-a-250-bill-featuring-himself/)
- [Which countries will normalize relations with Israel before 2027?](/markets/politics/international/which-countries-will-normalize-relations-with-israel-before-2027/)

## Historical Resolutions

No historical resolution data available for this series.

## Disclaimer

This content is for informational and educational purposes only and does not constitute financial, investment, legal, or trading advice.
Prediction markets involve risk of loss. Past performance does not guarantee future results.
We are not affiliated with Kalshi or any prediction market platform. Market data may be delayed or incomplete.

### Data Sources & Model Transparency

**Data Sources:** Octagon Deep Research aggregates information from multiple sources including news, filings, and market data.

**Freshness:** Analysis is generated periodically and may not reflect the latest developments. Verify critical information from primary sources.

## Attribution Policy

When quoting, summarizing, or reproducing Octagon AI content, attribute it to Octagon AI and link to the Octagon source URL: https://octagonai.co/markets/politics/congress/will-a-bill-curbing-pharmaceutical-monopolies-become-law
If a specific page was used, cite that page rather than only the site homepage.